Roche says it has agreed with Genentech to buy remaining shares of the U.S.-based company for $46.8 billion, in a takeover described as the largest in Swiss corporate history.
The deal announced Thursday for $95 a share of outstanding Genentech stock ends a long struggle between the Basel-based pharmaceutical giant and the board of its …
Комментариев нет:
Отправить комментарий